{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["atezolizumab"]],"indication":"previously-treated advanced thymic carcinoma","name":"ML41253","nct_id":"NCT04321330","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ml41253-nct04321330. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.","label":"Atezolizumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-06-03","type":"ACTUAL"},"conditions":["Carcinoma, Thymic"],"enrollment":{"count":34,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL3280A; RO5541267; Tecentriq"],"type":"DRUG"}],"last_update":"2024-06-11","lead_sponsor":"Hoffmann-La Roche","official_title":"An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-07-16","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective response rate (ORR)","timeFrame":"Baseline up to approximately 3.5 years"}],"references":[{"citation":"Remon J, Girard N, Novello S, de Castro J, Bigay-Game L, Bernabe R, Greillier L, Mosquera J, Cousin S, Juan O, Sampayo M, Besse B. PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clin Lung Cancer. 2022 May;23(3):e243-e246. doi: 10.1016/j.cllc.2021.07.008. Epub 2021 Jul 20.","pmid":"34393061","type":"DERIVED"}],"start_date":{"date":"2020-08-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma","url":"https://clinicaltrials.gov/study/NCT04321330"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ml41253-nct04321330"}